Search

Your search keyword '"Schmidtmann Irene"' showing total 1,063 results
Start Over Author "Schmidtmann Irene"
1,063 results on '"Schmidtmann Irene"'

8. Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab

Author

Gairing, Simon Johannes, Mildenberger, Philipp, Gile, Jennifer, Artusa, Fabian, Scheiner, Bernhard, Leyh, Catherine, Lieb, Sabine, Sinner, Friedrich, Jörg, Vincent, Fruendt, Thorben, Himmelsbach, Vera, Abedin, Nada, Sahin, Cennet, Böttcher, Katrin, Schuhbaur, Jasmin, Labuhn, Simon, Korolewicz, James, Fulgenzi, Claudia A.M., D'Alessio, Antonio, Zanuso, Valentina, Hucke, Florian, Röhlen, Natascha, Ben Khaled, Najib, Ramadori, Eleonora, Müller, Lukas, Weinmann, Arndt, Kloeckner, Roman, Galle, Peter Robert, Tran, Nguyen H., Venkatesh, Sudhakar K., Teufel, Andreas, Ebert, Matthias, De Toni, Enrico N., Waldschmidt, Dirk-Thomas, Marquardt, Jens U., Bettinger, Dominik, Peck-Radosavljevic, Markus, Geier, Andreas, Reiter, Florian P., Rimassa, Lorenza, Pinato, David J., Roderburg, Christoph, Ettrich, Thomas, Bitzer, Michael, Scheble, Veit, Ehmer, Ursula, Berres, Marie-Luise, Finkelmeier, Fabian, Gonzalez-Carmona, Maria Angeles, von Felden, Johann, Schulze, Kornelius, Venerito, Marino, van Bömmel, Florian, Jochheim, Leonie S., Pinter, Matthias, Mohr, Raphael, Ilyas, Sumera I., Schmidtmann, Irene, and Foerster, Friedrich

Published
2025
Full Text
View/download PDF

12. Recovery of right ventricular function after intermediate-risk pulmonary embolism: results from the multicentre Pulmonary Embolism International Trial (PEITHO)-2

Author

Mavromanoli, Anna C., Barco, Stefano, Ageno, Walter, Bouvaist, Hélène, Brodmann, Marianne, Cuccia, Claudio, Couturaud, Francis, Dellas, Claudia, Dimopoulos, Konstantinos, Duerschmied, Daniel, Empen, Klaus, Faggiano, Pompilio, Ferrari, Emile, Galiè, Nazzareno, Galvani, Marcello, Ghuysen, Alexandre, Giannakoulas, George, Huisman, Menno V., Jiménez, David, Kozak, Matija, Lang, Irene M., Meneveau, Nicolas, Münzel, Thomas, Palazzini, Massimiliano, Petris, Antoniu Octavian, Piovaccari, Giancarlo, Salvi, Aldo, Schellong, Sebastian, Schmidt, Kai-Helge, Verschuren, Franck, Schmidtmann, Irene, Toenges, Gerrit, Klok, Frederikus A., and Konstantinides, Stavros V.

Published
2023
Full Text
View/download PDF

14. LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases--a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial

Author

Schimanski Carl, Möhler Markus, Schön Michael, van Cutsem Eric, Greil Richard, Bechstein Wolf, Hegewisch-Becker Susanna, von Wichert Götz, Vöhringer Matthias, Heike Michael, Heinemann Volker, Peeters Marc, Kanzler Stephan, Kasper Stefan, Overkamp Friedrich, Schröder Jan, Seehofer Daniel, Kullmann Frank, Linz Bernhard, Schmidtmann Irene, Smith-Machnow Victoria, Gockel Ines, Lang Hauke, and Galle Peter R

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background 15-20% of all patients initially diagnosed with colorectal cancer develop metastatic disease and surgical resection remains the only potentially curative treatment available. Current 5-year survival following R0-resection of liver metastases is 28-39%, but recurrence eventually occurs in up to 70%. To date, adjuvant chemotherapy has not improved clinical outcomes significantly. The primary objective of the ongoing LICC trial (L-BLP25 In Colorectal Cancer) is to determine whether L-BLP25, an active cancer immunotherapy, extends recurrence-free survival (RFS) time over placebo in colorectal cancer patients following R0/R1 resection of hepatic metastases. L-BLP25 targets MUC1 glycoprotein, which is highly expressed in hepatic metastases from colorectal cancer. In a phase IIB trial, L-BLP25 has shown acceptable tolerability and a trend towards longer survival in patients with stage IIIB locoregional NSCLC. Methods/Design This is a multinational, phase II, multicenter, randomized, double-blind, placebo-controlled trial with a sample size of 159 patients from 20 centers in 3 countries. Patients with stage IV colorectal adenocarcinoma limited to liver metastases are included. Following curative-intent complete resection of the primary tumor and of all synchronous/metachronous metastases, eligible patients are randomized 2:1 to receive either L-BLP25 or placebo. Those allocated to L-BLP25 receive a single dose of 300 mg/m2 cyclophosphamide (CP) 3 days before first L-BLP25 dose, then primary treatment with s.c. L-BLP25 930 μg once weekly for 8 weeks, followed by s.c. L-BLP25 930 μg maintenance doses at 6-week (years 1&2) and 12-week (year 3) intervals unless recurrence occurs. In the control arm, CP is replaced by saline solution and L-BLP25 by placebo. Primary endpoint is the comparison of recurrence-free survival (RFS) time between groups. Secondary endpoints are overall survival (OS) time, safety, tolerability, RFS/OS in MUC-1 positive cancers. Exploratory immune response analyses are planned. The primary endpoint will be assessed in Q3 2016. Follow-up will end Q3 2017. Interim analyses are not planned. Discussion The design and implementation of such a vaccination study in colorectal cancer is feasible. The study will provide recurrence-free and overall survival rates of groups in an unbiased fashion. Trial Registration EudraCT Number 2011-000218-20

Published
2012
Full Text
View/download PDF

15. Cancer risk among residents of Rhineland-Palatinate winegrowing communities: a cancer-registry based ecological study

Author

König Jochem, Husmann Gabriele, Hammer Gaël, Seidler Andreas, Krtschil Anne, Schmidtmann Irene, and Blettner Maria

Subjects
Industrial medicine. Industrial hygiene, RC963-969
Abstract

Abstract Aim To investigate the cancer risk among residents of Rhineland-Palatinate winegrowing communities in an ecological study. Methods On the basis of the Rhineland-Palatinate cancer-registry, we calculated age-adjusted incidence rate ratios for communities with a medium area under wine cultivation (>5 to 20 percent) and a large area under wine cultivation (>20 percent) in comparison with communities with a small area under wine cultivation (>0 to 5 percent). In a side analysis, standardized cancer incidence ratios (SIR) were computed separately for winegrowing communities with small, medium and large area under wine cultivation using estimated German incidence rates as reference. Results A statistically significant positive association with the extent of viniculture can be observed for non-melanoma skin cancer in both males and females, and additionally for prostate cancer, bladder cancer, and non-Hodgkin lymphoma in males, but not in females. Lung cancer risk is significantly reduced in communities with a large area under cultivation. In the side-analysis, elevated SIR for endocrine-related tumors of the breast, testis, prostate, and endometrium were observed. Conclusion This study points to a potentially increased risk of skin cancer, bladder cancer, and endocrine-mediated tumors in Rhineland-Palatinate winegrowing communities. However, due to the explorative ecologic study design and the problem of multiple testing, these findings are not conclusve for a causal relationship.

Published
2008
Full Text
View/download PDF

19. Project DECIDE, part II: decision-making places for people with dementia in Alzheimer’s disease: supporting advance decision-making by improving person-environment fit

Author

Florack, Janina, Abele, Christina, Baisch, Stefanie, Forstmeier, Simon, Garmann, Daniel, Grond, Martin, Hornke, Ingmar, Karakaya, Tarik, Karneboge, Jonas, Knopf, Boris, Lindl, Gregor, Müller, Tanja, Oswald, Frank, Pfeiffer, Nathalie, Prvulovic, David, Poth, Aoife, Reif, Andreas, Schmidtmann, Irene, Theile-Schürholz, Anna, Ullrich, Heiko, and Haberstroh, Julia

Published
2023
Full Text
View/download PDF

28. Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO study

Author

Klok, Frederikus A., Piazza, Gregory, Sharp, Andrew S.P., Ní Ainle, Fionnuala, Jaff, Michael R., Chauhan, Nikhil, Patel, Binal, Barco, Stefano, Goldhaber, Samuel Z., Kucher, Nils, Lang, Irene M., Schmidtmann, Irene, Sterling, Keith M., Becker, Dorothea, Martin, Nadine, Rosenfield, Kenneth, and Konstantinides, Stavros V.

Published
2022
Full Text
View/download PDF

30. Author Correction: Cross-ancestry genome-wide association analysis of corneal thickness strengthens link between complex and Mendelian eye diseases.

Author

Iglesias, Adriana I, Mishra, Aniket, Vitart, Veronique, Bykhovskaya, Yelena, Höhn, René, Springelkamp, Henriët, Cuellar-Partida, Gabriel, Gharahkhani, Puya, Bailey, Jessica N Cooke, Willoughby, Colin E, Li, Xiaohui, Yazar, Seyhan, Nag, Abhishek, Khawaja, Anthony P, Polašek, Ozren, Siscovick, David, Mitchell, Paul, Tham, Yih Chung, Haines, Jonathan L, Kearns, Lisa S, Hayward, Caroline, Shi, Yuan, van Leeuwen, Elisabeth M, Taylor, Kent D, Blue Mountains Eye Study - GWAS group, Bonnemaijer, Pieter, Rotter, Jerome I, Martin, Nicholas G, Zeller, Tanja, Mills, Richard A, Souzeau, Emmanuelle, Staffieri, Sandra E, Jonas, Jost B, Schmidtmann, Irene, Boutin, Thibaud, Kang, Jae H, Lucas, Sionne EM, Wong, Tien Yin, Beutel, Manfred E, Wilson, James F, Wellcome Trust Case Control Consortium 2 (WTCCC2), NEIGHBORHOOD consortium, Uitterlinden, André G, Vithana, Eranga N, Foster, Paul J, Hysi, Pirro G, Hewitt, Alex W, Khor, Chiea Chuen, Pasquale, Louis R, Montgomery, Grant W, Klaver, Caroline CW, Aung, Tin, Pfeiffer, Norbert, Mackey, David A, Hammond, Christopher J, Cheng, Ching-Yu, Craig, Jamie E, Rabinowitz, Yaron S, Wiggs, Janey L, Burdon, Kathryn P, van Duijn, Cornelia M, and MacGregor, Stuart

Subjects
Blue Mountains Eye Study - GWAS group, Wellcome Trust Case Control Consortium 2, NEIGHBORHOOD consortium, Eye Disease and Disorders of Vision
Abstract

Emmanuelle Souzeau, who contributed to analysis of data, was inadvertently omitted from the author list in the originally published version of this Article. This has now been corrected in both the PDF and HTML versions of the Article.

Published
2019

31. Cross-ancestry genome-wide association analysis of corneal thickness strengthens link between complex and Mendelian eye diseases.

Author

Iglesias, Adriana I, Mishra, Aniket, Vitart, Veronique, Bykhovskaya, Yelena, Höhn, René, Springelkamp, Henriët, Cuellar-Partida, Gabriel, Gharahkhani, Puya, Bailey, Jessica N Cooke, Willoughby, Colin E, Li, Xiaohui, Yazar, Seyhan, Nag, Abhishek, Khawaja, Anthony P, Polašek, Ozren, Siscovick, David, Mitchell, Paul, Tham, Yih Chung, Haines, Jonathan L, Kearns, Lisa S, Hayward, Caroline, Shi, Yuan, van Leeuwen, Elisabeth M, Taylor, Kent D, Blue Mountains Eye Study—GWAS group, Bonnemaijer, Pieter, Rotter, Jerome I, Martin, Nicholas G, Zeller, Tanja, Mills, Richard A, Souzeau, Emmanuelle, Staffieri, Sandra E, Jonas, Jost B, Schmidtmann, Irene, Boutin, Thibaud, Kang, Jae H, Lucas, Sionne EM, Wong, Tien Yin, Beutel, Manfred E, Wilson, James F, NEIGHBORHOOD Consortium, Wellcome Trust Case Control Consortium 2 (WTCCC2), Uitterlinden, André G, Vithana, Eranga N, Foster, Paul J, Hysi, Pirro G, Hewitt, Alex W, Khor, Chiea Chuen, Pasquale, Louis R, Montgomery, Grant W, Klaver, Caroline CW, Aung, Tin, Pfeiffer, Norbert, Mackey, David A, Hammond, Christopher J, Cheng, Ching-Yu, Craig, Jamie E, Rabinowitz, Yaron S, Wiggs, Janey L, Burdon, Kathryn P, van Duijn, Cornelia M, and MacGregor, Stuart

Subjects
Blue Mountains Eye Study—GWAS group, NEIGHBORHOOD Consortium, Wellcome Trust Case Control Consortium 2, Cornea, Humans, Marfan Syndrome, Corneal Diseases, Corneal Dystrophies, Hereditary, Keratoconus, Eye Diseases, Hereditary, Glaucoma, Open-Angle, Myopia, Ehlers-Danlos Syndrome, Proteoglycans, Gene Expression, Quantitative Trait, Heritable, Polymorphism, Single Nucleotide, Quantitative Trait Loci, Genome, Human, Asian Continental Ancestry Group, European Continental Ancestry Group, Transforming Growth Factor beta2, Genome-Wide Association Study, Loeys-Dietz Syndrome, Mendelian Randomization Analysis, Decorin, Lumican, Fibrillin-1, ADAMTS Proteins, Corneal Dystrophies, Hereditary, Eye Diseases, Glaucoma, Open-Angle, Quantitative Trait, Heritable, Polymorphism, Single Nucleotide, Genome, Human
Abstract

Central corneal thickness (CCT) is a highly heritable trait associated with complex eye diseases such as keratoconus and glaucoma. We perform a genome-wide association meta-analysis of CCT and identify 19 novel regions. In addition to adding support for known connective tissue-related pathways, pathway analyses uncover previously unreported gene sets. Remarkably, >20% of the CCT-loci are near or within Mendelian disorder genes. These included FBN1, ADAMTS2 and TGFB2 which associate with connective tissue disorders (Marfan, Ehlers-Danlos and Loeys-Dietz syndromes), and the LUM-DCN-KERA gene complex involved in myopia, corneal dystrophies and cornea plana. Using index CCT-increasing variants, we find a significant inverse correlation in effect sizes between CCT and keratoconus (r = -0.62, P = 5.30 × 10-5) but not between CCT and primary open-angle glaucoma (r = -0.17, P = 0.2). Our findings provide evidence for shared genetic influences between CCT and keratoconus, and implicate candidate genes acting in collagen and extracellular matrix regulation.

Published
2018

37. Project DECIDE, part 1: increasing the amount of valid advance directives in people with Alzheimer’s disease by offering advance care planning—a prospective double-arm intervention study

Author

Baisch, Stefanie, Abele, Christina, Theile-Schürholz, Anna, Schmidtmann, Irene, Oswald, Frank, Karakaya, Tarik, Müller, Tanja, Florack, Janina, Garmann, Daniel, Karneboge, Jonas, Lindl, Gregor, Pfeiffer, Nathalie, Poth, Aoife, Caba, Bogdan Alin, Grond, Martin, Hornke, Ingmar, Prvulovic, David, Reif, Andreas, Ullrich, Heiko, and Haberstroh, Julia

Published
2022
Full Text
View/download PDF

39. Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial

Author

Antonio, Jaime, Freire, Abelaira, Ageno, Walter, Akin, Ibrahim, Anusic, Toni, Barco, Stefano, Becker, Dorothea, Bertoletti, Laurent, Bettoni, Giuseppe, Binder, Harald, Brodmann, Marianne, Bouvaist, Hélène, Carels, Regina, Cuccia, Claudio, Couturaud, Francis, Dellas, Claudia, Di Pasquale, Giuseppe, Dimopoulos, Konstantinos, Dürschmied, Daniel, Empen, Klaus, Enea, Iolanda, Faggiano, Pompilio, Ferrari, Emile, Ficker, Joachim, Galiè, Nazzareno, Galvani, Marcello, Genth-Zotz, Sabine, Giannakoulas, George, Girard, Philippe, Gorbulev, Stanislav, Ghuysen, Alexandre, Held, Matthias, Hobohm, Lukas, Huisman, Menno V., Jiménez, David, Klok, Frederikus A., Konstantinides, Stavros V., Kozak, Matija, Kronfeld, Kai, Lang, Irene Marthe, Lankeit, Mareike, Lehmacher, Walter, Miguel, Concepcion Patricia Lopez, Martin, Nadine, Mavromanoli, Anna, Meneveau, Nicolas, Meyer, Guy, Münzel, Thomas, Palazzini, Massimiliano, Pareznik, Roman, Petris, Antoniu Octavian, Piovaccari, Giancarlo, Quitzau, Kurt, Parepa, Irinel Raluca, Martin, Purificacion Ramirez, Righini, Marc, Salvi, Aldo, Schellong, Sebastian, Schmidt, Kai-Helge, Schmidtmann, Irene, Toenges, Gerrit, Todea, Silviu Bogdan, Torbicki, Adam, Valerio, Luca, Vanassche, Thomas, Verschuren, Franck, Vida-Simiti, Luminita Animarie, Wolf-Pütz, Anamaria, Klok, Frederikus A, Mavromanoli, Anna C, Duerschmied, Daniel, Huisman, Menno V, and Konstantinides, Stavros V

Published
2021
Full Text
View/download PDF

41. Abstract 12399: Impact of Heart Failure and Chronic Kidney Disease on Clinical Outcome in Relation to Presence of Type-2 Diabetes Mellitus - Results From the Population-Based Gutenberg Health Study

Author

Troebs, Sven, Prochaska, Juergen H, Stuermlinger, Anna, Velmeden, David, Ley, Ludwin, Mueller, Felix, Heidorn, Marc, Schuch, Alexander, Koeck, Thomas, Schulz, Andreas, Schmidtmann, Irene, Michal, Matthias, Schuster, Andreas, Tuescher, Oliver, Weimann-Menke, Julia, Schattenberg, Joern M, Lackner, Karl J, Muenzel, Thomas, and Wild, Philipp S

Published
2022
Full Text
View/download PDF

42. FRI-194-YI Risk of all-cause mortality and adverse outcomes from steatotic liver disease and its subgroups in the general population

Author

Michel, Maurice, primary, Armandi, Angelo, additional, Gieswinkel, Alexander, additional, Schuster, Alexander, additional, Muenzel, Thomas, additional, Konstantinides, Stavros, additional, Michal, Matthias, additional, Straub, Beate, additional, Schmidtmann, Irene, additional, Tuescher, Oliver, additional, Wild, Philipp, additional, Lackner, Karl, additional, Galle, Peter R., additional, and Schattenberg, Jörn M, additional

Published
2024
Full Text
View/download PDF

47. Estimated Annual Healthcare Costs After Acute Pulmonary Embolism: Results From a Prospective Multicentre Cohort Study

Author

Mohr, Katharina; https://orcid.org/0009-0000-5718-0549, Mildenberger, Philipp; https://orcid.org/0000-0002-7367-1708, Neusius, Thomas; https://orcid.org/0000-0002-5097-9064, Christodoulou, Konstantinos C; https://orcid.org/0000-0002-5807-9212, Farmakis, Ioannis T; https://orcid.org/0000-0002-0586-6386, Kaier, Klaus; https://orcid.org/0000-0003-0837-6945, Barco, Stefano; https://orcid.org/0000-0002-2618-347X, Klok, Frederikus A; https://orcid.org/0000-0001-9961-0754, Hobohm, Lukas; https://orcid.org/0000-0002-4312-0366, Keller, Karsten; https://orcid.org/0000-0002-0820-9584, Becker, Dorothea; https://orcid.org/0000-0003-1924-0736, Abele, Christina; https://orcid.org/0000-0002-1991-0587, Bruch, Leonhard; https://orcid.org/0000-0002-7295-5805, Ewert, Ralf; https://orcid.org/0000-0002-6746-9925, Schmidtmann, Irene; https://orcid.org/0000-0001-8743-6752, Wild, Philipp S; https://orcid.org/0000-0003-4413-9752, Rosenkranz, Stephan; https://orcid.org/0000-0001-6237-1470, Konstantinides, Stavros V; https://orcid.org/0000-0001-6359-7279, Binder, Harald; https://orcid.org/0000-0002-5666-8662, Valerio, Luca; https://orcid.org/0000-0003-4466-0724, Mohr, Katharina; https://orcid.org/0009-0000-5718-0549, Mildenberger, Philipp; https://orcid.org/0000-0002-7367-1708, Neusius, Thomas; https://orcid.org/0000-0002-5097-9064, Christodoulou, Konstantinos C; https://orcid.org/0000-0002-5807-9212, Farmakis, Ioannis T; https://orcid.org/0000-0002-0586-6386, Kaier, Klaus; https://orcid.org/0000-0003-0837-6945, Barco, Stefano; https://orcid.org/0000-0002-2618-347X, Klok, Frederikus A; https://orcid.org/0000-0001-9961-0754, Hobohm, Lukas; https://orcid.org/0000-0002-4312-0366, Keller, Karsten; https://orcid.org/0000-0002-0820-9584, Becker, Dorothea; https://orcid.org/0000-0003-1924-0736, Abele, Christina; https://orcid.org/0000-0002-1991-0587, Bruch, Leonhard; https://orcid.org/0000-0002-7295-5805, Ewert, Ralf; https://orcid.org/0000-0002-6746-9925, Schmidtmann, Irene; https://orcid.org/0000-0001-8743-6752, Wild, Philipp S; https://orcid.org/0000-0003-4413-9752, Rosenkranz, Stephan; https://orcid.org/0000-0001-6237-1470, Konstantinides, Stavros V; https://orcid.org/0000-0001-6359-7279, Binder, Harald; https://orcid.org/0000-0002-5666-8662, and Valerio, Luca; https://orcid.org/0000-0003-4466-0724

Abstract

OBJECTIVE: Patients surviving acute pulmonary embolism (PE) necessitate long-term treatment and follow-up. However, the chronic economic impact of PE on European healthcare systems remains to be determined. METHODS AND RESULTS: We calculated the direct cost of illness during the first year after discharge for the index PE, analyzing data from a multicentre prospective cohort study in Germany. Main and accompanying readmission diagnoses were used to calculate DRG-based hospital reimbursements; anticoagulation costs were estimated from the exact treatment duration and each drug's unique national identifier; and outpatient post-PE care costs from guidelines-recommended algorithms and national reimbursement catalogues. Of 1017 patients enrolled at 17 centres, 958 (94%) completed ≥ 3-month follow-up; of those, 24% were rehospitalized (0.34 [95% CI 0.30-0.39] readmissions per PE survivor). Age, coronary artery, pulmonary and kidney disease, diabetes, and (in the sensitivity analysis of 837 patients with complete 12-month follow-up) cancer, but not recurrent PE, were independent cost predictors by hurdle gamma regression accounting for zero readmissions. Estimated rehospitalization cost was €1138 (95% CI 896-1420) per patient. Anticoagulation duration was 329 (IQR 142-365) days, with estimated average per-patient costs of €1050 (median 972; IQR 458-1197); costs of scheduled ambulatory follow-up visits amounted to €181. Total estimated direct per-patient costs during the first year after PE ranged from €2369 (primary analysis) to €2542 (sensitivity analysis). CONCLUSIONS: By estimating per-patient costs and identifying cost drivers of post-PE care, our study may inform decisions concerning implementation and reimbursement of follow-up programmes aiming at improved cardiovascular prevention. (Trial registration number: DRKS00005939).

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results